Background and Purpose: Radiotherapy (RT) is well accepted for therapy-refractory palmo-plantar eczema or psoriasis, despite of lacking evidence regarding beneficial long term effects. Furthermore, the optimal irradiation dose is unknown. We evaluated the outcome of RT with two different RT single/total dose (SD/TD) treatment policies. Patients and Methods: 28 consecutive patients with therapy-refractory eczema (n = 22) or psoriasis (n = 6) of palms and/or soles were irradiated twice a week either with a D max SD of 1 Gy (6/98-5/03; median TD: 12 Gy) or 0.5 Gy (6/03-7/04; median TD: 5 Gy). Median age was 52 years (27-71), median follow-up 20 months (4-76). Totally 88 regions were treated, 49 with 1 Gy, 39 with 0.5 Gy SD. Eight different symptoms were scored from 0 (absent) -3 (severe), giving a possible sum score of 0-24. Patients' rating of RT result was also documented (worse/stable/better/complete remission). Results: The sum score was 15 (6-23) before RT, 2 (0-16) at the end of RT, and 1 (0-21) at last follow-up, respectively. The improvement was highly significant in both treatment regimens. Better or complete remission by the patients were reported in 44 and 39 (= 83 out of 88) localisations, that was often stable during the follow-up. 5 (6%) regions in 3 (11%) patients didn't benefit from RT. Conclusion: RT reveals excellent results in palmo-plantar eczema or psoriasis. We recommend a SD of 0.5 Gy twice a week up to a TD of 4-5 Gy. 
Introduction
Eczema and psoriasis are common skin disorders affecting 1-5% of the adult population [17, 20] . Due to an often chronic natural history they represent a major cause of morbidity and disability [18, 20, 30] . In general there is no evidence from large, prospective randomised studies with long-term followup for the 3 current treatment options -topical corticosteroids, topical coal tar and PUVA/UVB [3, 20, 30] . For therapy-refractory disease radiotherapy (RT) is well accepted [22] , despite insufficient evidence for a comparative advantage of irradiation compared to the above mentioned treatment modalities.
Randomized controlled trials regarding RT (6 in palmar eczema, 1 in plantar eczema and 2 for palmo-plantar psoriasis, Table 1 ) do not fulfill current standards: they included low number of patients (14-30 patients) with a follow-up of only 1.3-6 months. Furthermore, the optimal irradiation dose is unknown [10, 28] .
The aim of this study was to evaluate the clinical longterm outcome of RT with two different treatment policies according to RT dose for patients with palmar and/or plantar eczema or psoriasis.
Patients and Methods
Between June 1998 and July 2004 34 consecutive patients were referred for RT from the Department of Dermatology due to chronic palmar and/or plantar eczema or psoriasis. 6 patients were not treated due to patient refusal. 28 patients (14 female; 14 male) received radiotherapy (RT) for eczema (n = 22) or psoriasis (n = 6). Median age was 52 years (range: 27-71 years). Before the referral to our institute patients were treated with different regimens. The median disease duration before RT was 84 months (range: 7-243 months).
The median number of regions to be irradiated was 2 (range: 1-10 regions) per patient, resulting in totally 88 regions. All patients received orthovoltage irradiation either with 43 kV (with Dermopan in 11 patients) or 50 kV (with Therapax in 17 patients).
Until May 2003 a single dose of 1 Gy (D max ) twice a week was used for 49 regions, and the median total dose was 12 Gy (range: 7-13 Gy), whereas afterwards our treatment policy was changed and consisted of 0.5 Gy (D max ) single dose twice a week for 39 regions up to a median total dose of 5 Gy (range: 2.5-8 Gy). Examinations were always done by both, a radiation oncologist (MN) and dermatologist (PI) according to a prospectively designed score, which was generated due to following symptoms (Table 2) : itching, pain, impairment of mobility, psychosocial burden, redness, hyperkeratosis, scaling and cracks. Each symptom was divided into 4 groups ranging from none (grade 0) up to severe (grade 3) in addition to mild or moderate symptoms (grade 1 or 2, respectively). Each treatment location (n = 88) was analyzed according to above mentioned categories with a score from 0-3, giving a sum score for all eight parameters (minimum to maximum score points: 0-24). Complete remission was defined by a sum score of 0. The score for each symptom as well as the sum score was documented at baseline before RT, at the end of RT and at last follow-up.
Statistical comparisons between the situation before irradiation and at last follow-up were done by the Mann-Whitney U-test. In addition patients were asked about their personal rating of RT response according to four possible groups: worse, stable, better and no symptoms (= complete remission).
The median follow-up (defined from the end of RT till last control) was 20 months (range: 4-76 months). Figure 1 and in Table 3 all patients were symptomatic before RT, most of them with a high sum score (median: 15; range: 6-23). Most common grade 3 symptoms were severe itching (69% of all regions) and intense pain (73% of all regions): Severe impairment of mobility and severe psychosocial burden were reported in 42% and 38%. Other symptoms like redness, hyperkeratosis, scaling and cracks were reported in 20% as grade 3. Only 5% of regions were free of pain, other symptoms were absent in 6-26%.
Results

As shown in
At the end of RT the median sum score was 2 (range: 0-16), and 20% experienced complete remission (sum score of 0). Figure 1 . Severity of symptoms before and after radiotherapy and at last control (see also Table 2 ).
Abbildung 1.
Ausprägung der einzelnen Symptome vor und nach Radiotherapie sowie bei der letzten Nachkontrolle (siehe auch Tabelle 2).
At last control the median sum score was 1 (range: 0-21), and 36% had complete remission (Table 3, Figures 2  and 3 ). RT had a similar impact on each symptom (Figure 1 ). The differences compared to the situation before RT were highly significant (Table 3) .
There was no marked difference between single doses of 0.5 Gy (median total dose of 5 Gy) and 1 Gy (median total dose of 12 Gy): the median sum score for both groups was 15 vs. 14 before RT, 2 vs. 2 at the end of RT and 0 vs. 2 at last control, respectively (Table 4) . A significant improvement could be documented in both treatment groups.
According to patients' reports initial symptoms were rated stable at the end of RT in 5 out of 88 regions (3 out of 28 patients), better in 44 regions, and 39 regions were reported as complete remission. At last follow-up complete remission was reported for 32 regions (28 out of the "complete remission" group and 4 out of the "better" group at the end of RT). All 5 with stable symptoms at the end of RT remained unchanged at last follow-up (Figure 1) . No region was rated worse by the patients, neither at the end of RT nor at last control.
We did not see any side effects due to radiotherapy.
Discussion
There is a long history for irradiation in benign diseases [25, 29] . First treatments by RT for chronic eczema and psoriasis were described in 1898 [11, 24] . Over decades the indication for RT in benign diseases was well accepted. In 1925 more pages were given to describing RT indications of various benign diseases than for cancer in the most comprehensive textbook for RT of that time [19] . The use of RT has decreased considerably as reports about carcinogenesis due to ionizing irradiation [1, 4] and new and better systemic and topical treatments have become available. However, e.g. in eczema and psoriasis of palms and soles RT is still a valid option after other therapeutic methods have failed [22] .
The efficacy of RT in chronic eczema and psoriasis is supported by the re- 1  42  48  42  48  29  33  2  26  30  12  14  1  1  3  16  18  0  0  3  3  Hyperkeratosis 0  20  23  50  57  64  73  < 0.0001  1  21  24  35  40  17  19  2  33  38  3  3  5  6  3  14  16  0  0  2  2  Scaling  0  5  6  45  51  49  56  < 0.0001  1  35  40  40  45  33  38  2  32  36  3  3  4  5  3  16  18  0  0  2  2  Cracks  0  17  19  64  73  72  82  < 0.0001  1  29  33  21  24  10  11  2  24  27  3  3  4  5  3  18  20  0  0  2  2 *p-values are given for each symptom at last control compared to the situation before irradiation. sults of randomized trials, all of them were performed in the eighties (Table 1 ). According to current standards they hardly fulfill criteria for evidence-based medicine [3, 20, 30] . They included low numbers of patients and follow-up was only 5 weeks to 6 months (median 4 months). Therefore outcome in the mid or long term is unknown. Severity-scores for symptoms were different and simplified encompassing several symptoms. Due to the absence of accepted severity-scores in both eczema and psoriasis [5, 20, 30, 31] a comparison of trials is difficult. Regarding RT single doses of 0.9 Gy -4 Gy and total doses of 2.7 Gy -24 Gy were used in these trials. Unfortunately newer data are lacking. Our study revealed several interesting findings: We have scored 8 different symptoms, and there was a marked reduction of severity in each symptom at the end of RT, which was quite stable till last follow-up. These improvements were highly significant.
Complete remission (CR) and improvement of symptoms were seen for a high proportion of treated areas at the end of RT according to patients' rating. CR and improvement were documented for almost all regions (39 + 44 = 83 out of 88), which remained stable in 68 areas (32 with CR and 36 with improvement) at last follow-up. On the other hand, the remaining 5 regions (3 patients) without change at the end of RT showed no improvement also during the follow-up.
Doctors' rating revealed also excellent results: CR (sum-score: 0) or nearly CR (sum-score: 1-4) was documented for 18 + 48 = 66 out of 88 regions at the end of RT, and for 32 + 31 = 63 out of 88 regions at last follow-up.
We could not see major differences between lower and higher doses of RT, both treatment schedules revealed highly significant rates of improvement. This is in accordance with the literature on irradiation in benign diseases [13, 23, overviews in 10 and 28] . The only systematic dose-finding study was performed on more than 500 localisations with eczema or psoriasis, and there was no difference between 0.6 Gy, 0.8 Gy and 1 Gy [10] . In a recent overview by Panizzon [22] single doses of 0.3 Gy to 1 Gy and total doses of 3 Gy to 12 Gy are recommended for inflammatory diseases including eczema and psoriasis.
The excellent results are in part different in comparison with previous published studies summarized in Table 1 . There is no obvious reason for that, however findings among randomized studies Table 4 . Changes of sum-score for all 88 localisations (bold) and for the subgroups treated with a single dose (SD) of 0.5 Gy and 1.0 Gy. are also inconsistent. A well conducted randomized study should be performed to show that radiotherapy might be an ideal treatment option for resistant cases to topical and physical treatments. Similar to other nonmalignant diseases [12, 21, 26] undertaking of a pattern of care study would be also desirable in palmoplantar eczema and psoriasis. It would be interesting to see how many radiotherapy centers actually treat chronic palmo-plantar eczema or psoriasis, and with which technique and dose. The potential risk of irradiation of a benign, non-life-threatening disease must be recognised. However, regarding the very low risk of radiation-induced cancer RT may be considered if other methods have not succeeded and if the consequences of no further treatment are unacceptable for the patient.
Conclusion
Topical steroids are the mainstay of the pharmacological treatment of palmo-plantar eczema and psoriasis. For patients with otherwise therapy-refractory eczema or psoriasis RT offers high rates of improvement or complete remission, which can last several years. RT should be taken into consideration in these patients. Both treatment regimens, low and higher dose irradiation, had highly significant improvement rates. Therefore, we propose a single dose of 0.5 Gy, twice a week, to a total dose of max. 5 Gy.
